82 Spam-Free Article(s) Found
Sort:
Relevance
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
NVS Novartis AG $85.13 $197.65B N/A
Article Searches
Lilly Reports Disappointing Data on Alzheimer's Candidate http://www.zacks.com/stock/news/760082/lilly-reports-disappointing-data-on-alzheimers-candidate?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-760082 Feb 11, 2020 - Eli Lilly's (LLY) Alzheimer's disease drug, solanezumab, fails to meet primary endpoint in a phase II/III investigator-led study.
Koninklijke Vopak NV (VOPKF) CEO Eelco Hoekstra on Q4 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4323529-koninklijke-vopak-nv-vopkf-ceo-eelco-hoekstra-on-q4-2019-results-earnings-call-transcript?source=feed_sector_transcripts Feb 12, 2020 - Koninklijke Vopak NV (OTCPK:VOPKF) Q4 2019 Earnings Conference Call February 12, 2020, 05:00 ET Company Participants Laurens de Graaf - Head, IR Eelco Hoekstra - Chairman & CEO Gerard Paulides - C
Barco NV (BCNAF) CEO Jan De Witte Q4 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4324506-barco-nv-bcnaf-ceo-jan-de-witte-q4-2019-results-earnings-call-transcript?source=feed_sector_transcripts Feb 14, 2020 - Barco NV (OTCPK:BCNAF) Q4 2019 Earnings Conference Call February 13, 2019 03:00 AM ET Company Participants Carl Vanden Bussche - Vice President of Investor Relations Jan De Witte - Chief Executive Off
KBC Group NV (KBCSF) CEO Johan Thijs on Q4 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4324519-kbc-group-nv-kbcsf-ceo-johan-thijs-on-q4-2019-results-earnings-call-transcript?source=feed_sector_transcripts Feb 14, 2020 -
Novartis (NVS) to Acquire The Medicines Company for $9.7B http://www.zacks.com/stock/news/636880/novartis-nvs-to-acquire-the-medicines-company-for-%2497b?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-636880 Nov 25, 2019 - Novartis (NVS) set to acquire The Medicines Company and add a promising candidate to its cardiovascular pipeline.
4 Big Drug Stocks Ripe for Takeover After NVS-MDCO Deal http://www.zacks.com/stock/news/638202/4-big-drug-stocks-ripe-for-takeover-after-nvs-mdco-deal?cid=CS-ZC-FT-analyst_blog|industry_focus-638202 Nov 26, 2019 - Here are four stocks that boast promising prospects and are most likely to be takeout targets.
Global Blood's (GBT) Oxbryta Secures FDA Approval for SCD http://www.zacks.com/stock/news/642646/global-bloods-gbt-oxbryta-secures-fda-approval-for-scd?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-642646 Nov 27, 2019 - Global Blood's (GBT) Oxbryta wins the FDA nod to address sickle cell disease in patients aged 12 years and above. The approval comes three months ahead of schedule.
Euronav NV Frontline IMO 2020 Strategies: Assessing Which Will Be Superior https://seekingalpha.com/article/4309663-euronav-nv-frontline-imo-2020-strategies-assessing-will-superior?source=feed_all_articles Nov 28, 2019 - IMO 2020 sulfur regulation goes into effect January 1, 2020.Frontline has chosen a scrubber strategy.Euronav has chosen a pre-purchase at bulk prices and store compliant fuel.The most economical strat
Why Novartis's $9.7 Billion Purchase of The Medicines Company Is Bad News for Amgen https://www.fool.com/investing/2019/12/02/why-novartis-97-billion-purchase-of-the-medicines.aspx?source=iedfolrf0000001 Dec 02, 2019 - Novartis's purchase comes with investigational cardiovascular drug inclisiran, a competitor with potential to dethrone Amgen's already embattled Repatha.
Regeneron Reports Positive Data on Rare Blood Disorder Drug http://www.zacks.com/stock/news/657613/regeneron-reports-positive-data-on-rare-blood-disorder-drug?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-657613 Dec 06, 2019 - Regeneron (REGN) announces positive top-line data from a phase II study on rare blood disorder drug.

Pages: 123456789

<<<Page 5>